Tag: Lung cancer

Vergent Bioscience’s breakthrough at STS 2024: VGT-309 enhances lung cancer surgery

businessnewstoday- January 29, 2024

At the 60th Annual Meeting of The Society of Thoracic Surgeons (#STS2024), Vergent Bioscience, a Minneapolis-based clinical-stage biotechnology company, presented compelling new data about VGT-309, ... Read More

Mirati Therapeutics secures UK approval for KRAZATI in advanced NSCLC

businessnewstoday- November 4, 2023

Mirati Therapeutics, Inc. (NASDAQ: MRTX), an innovative biotechnology company, has received conditional authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its ... Read More

Lilly’s Retevmo outperforms in trials for RET fusion-positive NSCLC and RET-mutant MTC

businessnewstoday- October 24, 2023

Eli Lilly (Lilly) has disclosed the results from two pivotal Phase 3 studies, LIBRETTO-431 and LIBRETTO-531, evaluating the efficacy of Retevmo in treating patients with ... Read More

ENHERTU receives EU approval for advanced non-small cell lung cancer

businessnewstoday- October 23, 2023

The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ... Read More

Bristol Myers Squibb to acquire Mirati Therapeutics in $4.8bn deal

businessnewstoday- October 9, 2023

Bristol Myers Squibb (NYSE: BMY) is set to acquire Mirati Therapeutics, Inc. (NASDAQ: MRTX) at $58.00 per share in a cash deal valued at $4.8 ... Read More

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for EU approval

businessnewstoday- September 16, 2023

AstraZeneca and Daiichi Sankyo's Enhertu has been recommended for approval in the European Union (EU) for the treatment of adult patients with advanced non-small cell ... Read More

Gilead’s EVOKE-02 study of Trodelvy, KEYTRUDA combo shows promise in NSCLC

businessnewstoday- September 10, 2023

Gilead Sciences, Inc. announced early data showcasing promising clinical activity of Trodelvy in combination with Merck's KEYTRUDA for first-line treatment of metastatic non-small cell lung ... Read More

Patritumab Deruxtecan Phase 2 trial unveils encouraging outcomes in metastatic NSCLC

businessnewstoday- September 10, 2023

The HERTHENA-Lung01 Phase 2 trial, presented at the 2023 World Conference on Lung Cancer by Daiichi Sankyo, demonstrated that Patritumab Deruxtecan has potential for treating ... Read More

Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor

businessnewstoday- July 11, 2023

AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 "ELUCIDATE" study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 ('617), ... Read More

Eagle Pharmaceuticals gets Pemfexy FDA approval for NSCLC

Raghuram Kadari- December 28, 2022

Eagle Pharmaceuticals has secured an additional indication for Pemfexy (pemetrexed injection) in the US, marking the fifth indication for the intravenous medication. Pemfexy in combination ... Read More